Compare STXS & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STXS | MXCT |
|---|---|---|
| Founded | 1990 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.1M | 136.0M |
| IPO Year | 2004 | 2021 |
| Metric | STXS | MXCT |
|---|---|---|
| Price | $1.29 | $1.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $4.00 | ★ $5.50 |
| AVG Volume (30 Days) | 1.1M | ★ 1.7M |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $29,346,617.00 | ★ $33,026,000.00 |
| Revenue This Year | $28.22 | N/A |
| Revenue Next Year | $30.47 | $18.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.35 | $0.64 |
| 52 Week High | $3.59 | $2.31 |
| Indicator | STXS | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 24.76 | 38.61 |
| Support Level | N/A | $1.08 |
| Resistance Level | $1.98 | $1.16 |
| Average True Range (ATR) | 0.14 | 0.09 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 0.76 | 6.10 |
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.